1. American Society of Pharmacovigilance. Pharmacovigilance. Accessed January 26, 2022.
  2. Brown MT, Bussell JK. Medication adherence: WHO cares?. Mayo Clinic Proceedings. 2011;86(4):304–314. doi:10.4065/mcp.2010.0575.
  3. Watanabe JH, McInnis T, & Hirsch JD. Cost of prescription drug-related morbidity and mortality. SAGE Journals. 2018;52(9):829–837. doi:10.1177/1060028018765159.
  4. Hakkarainen KM, Hedna K, Petzold M, Hägg S. Percentage of patients with preventable adverse drug reactions and preventability of adverse drug reactions – a meta-analysis. PLoS ONE. 2012;7(3):e33236. doi:10.1371/journal.pone.0033236.
  5. Brennan FX, et al. A naturalistic study of the effectiveness of pharmacogenetic testing to guide treatment in psychiatric patients with mood and anxiety disorders. Prim Care Companion CNS Discord. 2015;17(2). doi:10.4088/PCC.14m01717
  6. Perlis RH, et al. Pharmacogenetic testing among patients with mood and anxiety disorders is associated with decreased utilization and cost: A propensity-score matched study. Depression & Anxiety. 2018;35(10):946-952. doi:10.1002/da.22742
  7. Ahmed S, et al. Pharmacogenomics of drug metabolizing enzymes and transporters: relevance to precision medicine. Genomics Proteomics Bioinformatics. 2016;14(5):298-313. doi:10.1016/j.gpb.2016.03.008
  8. Shah RR, et al. Addressing phenoconversion: the Achilles’ heel of personalized medicine. Br J Clin Pharmacol. 2015;79(2):222-40. doi: 10.1111/bcp.12441
  9. Food and Drug Administration. Table of pharmacogenetic associations. Accessed January 26, 2022.
  10. Genomind. (2020). Genomind customer satisfaction survey [Data file]. King of Prussia, PA: Genomind.
  11. Genomind. (2020). Survey of active Genomind clinicians [Data file]. King of Prussia, PA: Genomind.
  12. Leape LL, et al. The nature of adverse events in hospitalized patients. Results of the Harvard Medical Practice study II. N Engl J Med. 1991;324(6):377–384. doi:10.1056/NEJM199102073240605
  13. Food and Drug Administration. Preventable adverse drug reactions: a focus on drug interactions. Accessed January 26, 2022.
  14. Institute of Medicine. Preventing Medication Errors. Washington, DC: The National Academies Press; 2007. doi:10.17226/11623
  15. Saljoughian M. Polypharmacy and drug adherence in elderly patients. US Pharm. 2019;44(7):33-36.
  16. Mata-Cases M, et al. Prevalence and coprevalence of chronic comorbid conditions in patients with type 2 diabetes in Catalonia: a population based cross-sectional study. BMJ Open. 2019;9(10):e031281. doi:10.1136/bmjopen-2019-031281
  17. Da Silva BA, et al. The alarming reality of medication error: a patient case and review of Pennsylvania and National data. J Community Hosp Intern Med Perspect. 2016;6(4):31758. doi:10.3402/jchimp.v6.31758
  18. Centers for Disease Control and Prevention. Worker Productivity Measures. Accessed January 26, 2022.
  19. Perlis RH, et al. Randomized, controlled, participant- and rater-blind trial of pharmacogenomic test-guided treatment versus treatment as usual for major depressive disorder. Depress Anxiety. 2020;37(9):834-841. doi:10.1002/da.23029
  20. King CD, et al. Open-label pilot study of psychiatric pharmacogenetic testing in an adult psychiatric inpatient population. Elsevier. 2020. doi:10.1016/j.pmip.2020.100060
  21. Dowd D, et al. Predicting potential drug-drug-gene interactions in a population of individuals utilizing a community-based pharmacy. Presented at: Neuroscience Education Institute Congress; November 3-7, 2021; Colorado Springs, CO.
  22. Fagerness J, et al. Pharmacogenetic-guided psychiatric intervention associated with increased adherence and cost savings. Am J Manag Care. 2014;20(5):e146-56.
  23. Wood, et al. Veterans Affairs MedOpt Polypharmacy Study. Presented at: Psych Congress; October 3-6, 2019; San Diego, CA.
  24. Boland JR, et al. Clinical utility of pharmacogenetics-guided treatment of depression and anxiety. Personalized Medicine in Psychiatry. 2017;7:7-13. doi:10.1016/j.pmip.2017.11.001
  25. Rosenblat JD, et al. The effect of pharmacogenomic testing on response and remission rates in the acute treatment of major depressive disorder: a meta-analysis. J Affect Disord. 2018;241:484-491. doi:10.1016/j.jad.2018.08.056.
  26. Bousman CA, et al. Pharmacogenetic tests and depressive symptom remission: a meta-analysis of randomized controlled trials. Pharmacogenomics. 2019;20(1):37-47. doi:10.2217/pgs-2018-0142
  27. David V, et al. An analysis of pharmacogenomic-guided pathways and their effect on medication changes and hospital admissions: a systematic review and meta-analysis. Front. Genet. 2021;12:698148. doi: 10.3389/fgene.2021.698148
  28. Nasdaq. Why prioritizing mental health is good for employees and employers. Accessed January 26, 2022.
  29. Krause DS, Dowd D. Use of a consultation service following pharmacogenetic testing in psychiatry. Pharmacogenomics. 2022;23:5:327-333. doi:10.2217/pgs-2021-0121